| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99233 |
Prolong inpt eval add15 m |
24,994 |
8,400 |
$833K |
| 99223 |
Prolong inpt eval add15 m |
6,642 |
6,456 |
$388K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,793 |
13,530 |
$182K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
3,975 |
3,844 |
$149K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
22,219 |
21,469 |
$129K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
4,062 |
1,493 |
$98K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,754 |
1,752 |
$58K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
969 |
935 |
$21K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
313 |
313 |
$11K |
| 99222 |
Initial hospital care, per day, moderate complexity |
211 |
207 |
$11K |
| 90686 |
|
1,328 |
1,327 |
$8K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
85 |
41 |
$7K |
| 0011A |
|
209 |
208 |
$7K |
| 0012A |
|
184 |
184 |
$7K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
414 |
411 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,635 |
1,594 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
385 |
372 |
$2K |
| 0001A |
|
41 |
41 |
$2K |
| 97802 |
|
349 |
348 |
$940.85 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
517 |
511 |
$781.67 |
| 99217 |
|
32 |
32 |
$717.65 |
| 81002 |
|
985 |
967 |
$648.71 |
| 0002A |
|
17 |
17 |
$640.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
965 |
963 |
$608.37 |
| 99460 |
|
14 |
13 |
$524.08 |
| 99221 |
|
13 |
13 |
$412.05 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
12 |
12 |
$407.48 |
| 99215 |
Prolong outpt/office vis |
12 |
12 |
$401.15 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
164 |
163 |
$389.61 |
| 87807 |
|
85 |
83 |
$198.59 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
15 |
15 |
$143.40 |
| 85018 |
|
432 |
429 |
$68.00 |
| 87428 |
|
15 |
15 |
$63.59 |
| 3078F |
|
21,519 |
20,720 |
$62.41 |
| 92551 |
|
118 |
118 |
$54.18 |
| 90656 |
|
30 |
30 |
$27.00 |
| 81025 |
|
109 |
107 |
$24.93 |
| 3074F |
|
21,979 |
21,139 |
$0.04 |
| 1160F |
|
257 |
255 |
$0.01 |
| G8482 |
Influenza immunization administered or previously received |
279 |
278 |
$0.01 |
| 3008F |
|
7,721 |
7,506 |
$0.01 |
| 1000F |
|
392 |
388 |
$0.01 |
| 0502F |
|
276 |
232 |
$0.00 |
| 3077F |
|
674 |
660 |
$0.00 |
| 99173 |
|
135 |
135 |
$0.00 |
| 3725F |
|
68 |
68 |
$0.00 |
| 99201 |
|
17 |
14 |
$0.00 |
| 3079F |
|
4,253 |
4,166 |
$0.00 |
| 3075F |
|
1,524 |
1,501 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
12 |
12 |
$0.00 |
| 3048F |
|
37 |
37 |
$0.00 |
| 3080F |
|
70 |
69 |
$0.00 |
| 99402 |
|
14 |
14 |
$0.00 |